New meta-analysis of the assessment of the cardiovascular risk of rosiglitazone and its potential sequels
https://doi.org/10.14341/probl200753651-54
Abstract
On May 21, 2007, a meta-analysis was posted on the website of one of the most respected medical journals in the world, New England Journal of Medicine, which attracted close attention of not only healthcare professionals, but also the general public, and caused an active discussion on leading clinical journals and in the media.
The purpose of this meta-analysis, which included 42 relatively short-term (24–53 weeks) clinical trials, including 2 large ones, DREAM (A Diabetes Outcome Prevention Trial) and ADOPT (Diabetes Reduction Assessment with Ramipiril and Posiglitazone), was to assess the effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular disease. The participants in the studies were about 28 thousand patients with T2DM, of which 15,560 received treatment regimens containing rosiglitazone, and 12,283 (control group) received placebo or regimens containing other antidiabetic drugs (metformin, sulfonylurea derivatives, mainly glibenclamide, or insulin).
According to the results of meta-analysis, the use of rosiglitazone was associated with a significantly higher cardiovascular risk than the use of placebo and other hypoglycemic agents (see table). The risk of developing myocardial infarction in the rosiglitazone therapy group exceeded that in the control group by 43%, and the risk of death from cardiovascular causes by 64%.
References
1. Карпов О. И. // Рус. мед. жури. - 2006. - № 26. - С. 3- 6.
2. Avandia: Available at: http://www.emea.europa.eu/humandocs/Humans/EPAR/avandia/avandia.htm
3. Avandia (rosiglitazone maleate) tablets: prescribing information. Research Triangle Park, NC: GlaxoSmithKline, 2007 (package insert), http://www.fda.gov/cder/foi/label/2007/021071s0231bl.pdf.
4. Chiquette E., Ramirez G., Defronzo R. // Arch. Intern. Med. - 2004. - Vol. 164, N 19. - P. 2097-2104.
5. Dormandy J. A., Charbonnel В., Eckland D. J. et al. // Lancet. - 2005. - Vol. 366. - P. 1279-1289.
6. The DREAM Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial // Lancet. - 2006. - Vol. 368. - P. 1096-1105.
7. EMEA Statement On Recent Publication On Cardiac Safety Of Rosiglitazone (Avandia, Avandamet, Avaglim), Europe. Available at: http://www.emea.europa.eu/pdfs/general/direct/pr/23005707en.pdf.
8. FDA Issues Safety Alert on Avandia. FDA News. Available at: http://www.fda.gov/bbs/topics/NEVS/2007/NEW0I636.html.
9. Fredenrich A., Grimaldi P. А. Ц Diabetes Metab. - 2005. - Vol 31, N 1.-P. 23-27.
10. Grey A., Holland M., Gamble G. et al. // J. Clin. Endocrinol. Metab. - 2007. - Vol. 92, N 4. - P. 1305-1310.
11. Hoberbosch W. // Here. - 2007. - Bd 32, N 1. - S. 51-57.
12. Home P. D., Pocock S. J., Beck-Nielsen H. et al. // Diabetologia. - 2005. - Vol. 48. - P. 1726-1735.
13. Home P. D., Pocock S. J., Beck-Nielsen H. et al. Rosiglitazone evaluated for cardiovascular outcomesan interim analysis. N. Engl. J. Med. 2007; DOI: 0.1056/NEJMoa073394. Available at: <http://www.nejm.org>.
14. Hughes S. The Rosiglitazone Aftermath: Legitimate Concerns or Hype? Heartwire 2007. Available at: http://www.med-scape.com/viewarticle/557198.
15. Kahn S. E, Haffner S. M., Heise M. A. et al. // N. Engl. J. Med. - 2006. - Vol. 355. - P. 2427-2443.
16. Kannel W. В., McGee D. L. // Circulation. - 1979. - Vol 59. - P. 8-13.
17. Krentz A. J. // Expert. Opin. Drug Saf. - 2006. - Vol. 5. N 6. - P. 827-834.
18. Nainggolan L. Rosiglitazone Meta-Analysis Continues to Drive Controversy in Second Week. May 30, 2007. Available at: http://www.medscape.com/viewarticle/557511
19. Nathan D. M., Base J. В., Davidson M. B. et al. // Diabetes Care. - 2006. - Vol. 29, N 8. - P. 1963-1972.
20. Nesto R. W., Bell D., Bonow R. O. et al. Circulation. - 2003. -Vol. 108.-P. 2941-2948.
21. Nissen S. E, Wolski K., Topol E. J. // J. A. M. A. - 2005. -Vol. 294. - P. 2581-2586.
22. Nissen S. E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes, www.nejm.org May 21, 2007 (10.1056/NEJMoa072761).
23. Psaty В., Furberg C. Rosiglitazone and cardiovascular risk. N. Engl. J. Med. 2007; DOI:l0.1056/NEJMe078099. Available at: http://www.nejm.org.
24. Ramsdell J. W, Braunstein S. N., Stephens J. M. et al. // Pharmacoeconomics. - 2003. - Vol. 21, N 11. - P. 819-837.
25. Rubenstrunk A., Hanf R., Hum D. W. et al. // Biochim. Biophys. Acta. - 2007. - Feb. 24; [Epub ahead of print].
26. Saul S. Test of drug for diabetes in jeopardy. New York Times, May 26, 2007. Available at: http://www.nyiimes.com.
27. Statement from the American College of Cardiology, American Diabetes Association and American Heart Association Related to NEJM article, 'Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes*. http://diabetes.org/diabetesnewsarticle.jsp7storyld = I5ll5339@filename = 2007052 l/T.xml.
28. Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). // Lancet. - 1998. -Vol. 352. - P. 837-853.
29. Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) // Lancet. - 1998. - Vol. 352. - P. 854-865.
30. Yaturu S., Bryant В., Jain S. K. // Diabetes Care. - 2007. - Vol. 30. - P. 1574-1576.
Review
For citations:
Ushkalova E.A. New meta-analysis of the assessment of the cardiovascular risk of rosiglitazone and its potential sequels. Problems of Endocrinology. 2007;53(6):51-54. (In Russ.) https://doi.org/10.14341/probl200753651-54
Views:
563
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
.jpg){kind=logo}
